Last reviewed · How we verify

NCT07055152: REVEAL

Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients

Recruiting now Last updated 8 July 2025
What this trial tests

trial in MINOCA in 90 participants. Currently enrolling.

Timeline
1 January 2025
Primary endpoint
1 January 2026
1 January 2027

Quick facts

Lead sponsorUniversity of Pisa
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment90
Start date1 January 2025
Primary completion1 January 2026
Estimated completion1 January 2027
Sites1 location across Italy

Conditions studied

Sponsor

University of Pisa

Who can join

Eligibility, any sex, with MINOCA or STEMI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate microvascular dysfunction through OCTA in MINOCA patients. In order to better understand the condition, OCTA will also be performed in two matched patient groups: healthy controls and ACS patients. The study will compare the retinal microvascular parameters across these groups to determine differences in microvascular function in MINOCA patients. Additionally, in the MINOCA subgroup, the study will further evaluate the differences in microvascular dysfunction within specific subsets of patients (e.g., Takotsubo, vasospastic angina, microvascular angina, patients with evidence of plaque erosion) to understand the variability and potential mechanisms underlying each subgroup of MINOCA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for MINOCA

Currently open trials in the same condition.

Other University of Pisa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07055152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing